Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

To read all of these articles and more, visit centerforbiosimilars.com.

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.